Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Gyre Therapeutics (GYRE) over the last 11 years, with Sep 2025 value amounting to $668,000.

  • Gyre Therapeutics' Capital Expenditures fell 3.61% to $668,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $981,000, marking a year-over-year decrease of 79.15%. This contributed to the annual value of $2.3 million for FY2024, which is 72.82% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Capital Expenditures of $668,000 as of Q3 2025, which was up 160.94% from $256,000 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Capital Expenditures ranged from a high of $2.5 million in Q2 2023 and a low of -$65,000 during Q4 2024.
  • For the 3-year period, Gyre Therapeutics' Capital Expenditures averaged around $1.1 million, with its median value being $693,000 (2024).
  • Per our database at Business Quant, Gyre Therapeutics' Capital Expenditures surged by 152.31% in 2021 and then crashed by 102.80% in 2024.
  • Gyre Therapeutics' Capital Expenditures (Quarterly) stood at $492,000 in 2021, then reached $2.3 million in 2023, then crashed by 102.80% to -$65,000 in 2024, then decreased by 3.61% to $668,000 in 2025.
  • Its Capital Expenditures stands at $668,000 for Q3 2025, versus $256,000 for Q2 2025 and $122,000 for Q1 2025.